Continue reading→

At 11 years old, Jaheim Whigham (center) is the youngest and smallest patient to receive the 50cc SynCardia temporary Total Artificial Heart. (Photo: Jan Terry, Ann & Robert H. Lurie Children’s Hospital of Chicago)Continue reading→

Continue reading→

SenesTech, Inc. (SNES), a developer of proprietary technologies for managing animal pest populations through fertility control is ramping up manufacturing capabilities to meet demand in 2017 and beyond for the company’s innovative new rodent control technology, ContraPest. The Company’s existing manufacturing capacity, estimated at 300,000 liters per year, is expected to double under the current expansion plans.Continue reading→

2017 VENTURE MADNESS COMPETITION – VOTE FOR THE PEOPLE’S CHOICE AWARD by 5:00 PM, on January 24^thContinue reading→

Submission Window Open through February 17th!!Continue reading→

SenesTech, Inc. (Nasdaq: SNES), a developer of novel proprietary technologies for managing animal pest populations through fertility control, visited the Nasdaq MarketSite in Times Square to ring the closing bell on Friday, January 20, 2017.Continue reading→

Applications for 2017 Are Now OpenContinue reading→

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its new state-of-the-art laboratory facility in Phoenix, AZ based on results of a recent onsite inspection as part of the CAP’s Accreditation Programs. 

Continue reading→

Continue reading→